Payment overview · 2025
General Payments
$34.02
2 reported records · 2 companies
Healthcare provider profile · identity verified
Eric Samuel Hansen, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · VERNON, NJ · NPI 1306823364
Verified facts
What the public records show
CMS Open Payments records show Eric Samuel Hansen, D.O. received $34.02 in general payments during 2025 across 2 reported records.
Radius Health, Inc. accounted for 54.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $18.51 | 54.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.51 | 45.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $34.02 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 817 | 210 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 796 | 218 |
| Levothyroxine Sodium | Levothyroxine Sodium | 722 | 163 |
| Atorvastatin Calcium | Atorvastatin Calcium | 593 | 165 |
| Losartan Potassium | Losartan Potassium | 553 | 129 |
| Metoprolol Succinate | Metoprolol Succinate | 426 | 104 |
| Metformin Hcl Er | Metformin Hcl | 402 | 102 |
| Lisinopril | Lisinopril | 330 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 268 | 93 |
| Escitalopram Oxalate | Escitalopram Oxalate | 242 | 51 |
| Simvastatin | Simvastatin | 242 | 67 |
| Glimepiride | Glimepiride | 236 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 219 | 62 |
| Alprazolam | Alprazolam | 217 | 66 |
| Furosemide | Furosemide | 184 | 55 |
| Januvia | Sitagliptin Phosphate | 180 | 35 |
| Alendronate Sodium | Alendronate Sodium | 165 | 59 |
| Ezetimibe | Ezetimibe | 161 | 42 |
| Allopurinol | Allopurinol | 153 | 40 |
| Cefuroxime | Cefuroxime Axetil | 152 | 126 |
| Omeprazole | Omeprazole | 152 | 44 |
| Carvedilol | Carvedilol | 142 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 134 | 29 |
| Metformin Hcl | Metformin Hcl | 132 | 37 |
| Jardiance | Empagliflozin | 124 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 123 | 105 |
| Valsartan | Valsartan | 121 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 50 |
| Methylprednisolone | Methylprednisolone | 113 | 95 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 32 |
| Gabapentin | Gabapentin | 106 | 27 |
| Potassium Chloride | Potassium Chloride | 94 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 92 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 87 | 74 |
| Donepezil Hcl | Donepezil Hcl | 83 | 12 |
| Sertraline Hcl | Sertraline Hcl | 83 | 25 |
| Synthroid | Levothyroxine Sodium | 82 | 20 |
| Atenolol | Atenolol | 80 | 23 |
| Eliquis | Apixaban | 76 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 75 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 72 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 72 | 17 |
| Tramadol Hcl | Tramadol Hcl | 70 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 69 | 50 |
| Ozempic | Semaglutide | 67 | 11 |
| Cefdinir | Cefdinir | 62 | 52 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 59 | 14 |
| Tradjenta | Linagliptin | 58 | 14 |
| Montelukast Sodium | Montelukast Sodium | 57 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 17 |
| Azithromycin | Azithromycin | 55 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 14 |
| Famotidine | Famotidine | 53 | 14 |
| Lorazepam | Lorazepam | 53 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 37 |
| Trazodone Hcl | Trazodone Hcl | 47 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 46 | 13 |
| Warfarin Sodium | Warfarin Sodium | 46 | suppressed |
| Meloxicam | Meloxicam | 45 | 21 |
| Torsemide | Torsemide | 44 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 12 |
| Finasteride | Finasteride | 39 | 12 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 38 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 37 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 12 |
| Mometasone Furoate | Mometasone Furoate | 34 | 29 |
| Ramipril | Ramipril | 34 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Gemfibrozil | Gemfibrozil | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 27 |
| Clonazepam | Clonazepam | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 22 |
| Naproxen | Naproxen | 29 | 22 |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Prednisone | Prednisone | 24 | 15 |
| Trulicity | Dulaglutide | 24 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Belsomra | Suvorexant | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 18 |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | 14 |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 14 |
| Valacyclovir | Valacyclovir Hcl | 19 | 16 |
| Nystatin | Nystatin | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 14 | suppressed |
| Ofloxacin | Ofloxacin | 14 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Levoxyl | Levothyroxine Sodium | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $34.02 · 2 records | Radius Health, Inc. | Ozempic, Rybelsus, Tymlos | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error